Patents by Inventor Lawrence Edward Stramm

Lawrence Edward Stramm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
    Patent number: 7223728
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: May 29, 2007
    Assignee: Eli Lilly and Company
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, William Terry Johnson, Louis Vignati
  • Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
    Publication number: 20040127414
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Application
    Filed: October 6, 2003
    Publication date: July 1, 2004
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, William Terry Johnson, Louis Vignati
  • Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
    Patent number: 6660716
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: December 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, William Terry Johnson, Vignati Louis
  • Method of treating insulin resistance
    Patent number: 5939387
    Abstract: The present invention is in the field of human medicine, particularly in the treatment of Non-insulin Dependent Diabetes Mellitus (NIDDM) and other insulin resistant states such as those associated with obesity and aging. The invention provides a method of treating insulin resistant mammals, which comprises administering to a mammal in need thereof a growth hormone releasing agent.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Carol Lynn Broderick, Richard Dennis DiMarchi, Mark Louis Heiman, Lawrence Edward Stramm
  • Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
    Patent number: RE40876
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: August 18, 2009
    Assignee: Eli Lilly and Company
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, Louis Vignati, William Terry Johnson